Loading provider…
Loading provider…
Hematology & Oncology Physician in Madison, WI
NPI: 1003838145Primary Practice Location
UNIVERSITY OF WI HOSPITALS & CLINICS AUTHORITY
1675 Highland Ave, Madison, WI
Primary Employer
University of Wisconsin Medical Foundation, Inc
uwhealth.org
HQ Phone
Get MD Sam's Phone Numberphone_androidMobile
Get MD Sam's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardWI State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 80 | 179 |
| 2 | 99213Established patient office or other outpatient visit, typically 15 minutes | 58 | 90 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 25 | 25 |
| 4 | 36415Insertion of needle into vein for collection of blood sample | 20 | 28 |
| 5 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 19 | 37 |
Advancing the Clinician Educator Career Pathway in Oncology.
The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids.
Authors: Somnay, Y, Lubner, S, Gill, H, Matsumura, J B, Chen, H
Journal: Cancer Gene Ther
Publication Date: 2016-09-16
Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.
Authors: Rama Suresh, Joel Picus, Steven Sorscher, Parvin Peddi, Christine Menias, David Linehan, Albert Lockhart
Publication Date: 2012-09-12
Lead Sponsor: Howard S Hochster
Collaborators: Genentech, Inc., Rutgers Cancer Institute of New Jersey
Intervention / Treatment: DRUG: Atezolizumab, DRUG: Bevacizumab
Lead Sponsor: ECOG-ACRIN Cancer Research Group
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Carboplatin, DRUG: Temozolomide, OTHER: Laboratory Biomarker Analysis, DRUG: Cisplatin, DRUG: Capecitabine, DRUG: Etoposide
Lead Sponsor: SWOG Cancer Research Network
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Cisplatin, DRUG: Gemcitabine Hydrochloride, DRUG: Nab-paclitaxel